Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rangering i aksjer #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aksjekurs
$0.94180721
Markedsverdi
$22.26M
Endring (1 dag)
0.38%
Endring (1 år)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Kategori

Healthcare
P/S-forhold for Valbiotis SA (ALVAL)
P/S-forhold per July 2026 TTM: 20.66
Ifølge Valbiotis SA sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 20.66. Ved slutten av 2023 hadde selskapet et P/S-forhold på 13.17.
P/S-historikk for Valbiotis SA fra 2015 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 20.66 -84.94%
2024 137.18 942.04%
2023 13.17 -71.62%
2022 46.39 -77.96%
2021 210.51 1,341.15%
2020 14.61 -87.37%
2019 115.65 -24.97%
2018 154.14 -97.25%
2017 5.61K 10,113.84%
2016 54.92 355.39%
2015 12.06 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.33 -79.03%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.86 -52.26%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.53 -78.07%
US
UCB SA UCB SA
UCB SA
UCB.BR
5.72 -72.33%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.03 -22.43%
NL